Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer

International Journal of Cancer

Volumn 123, Issue 3, 2008, Pages 569-576

  Mertz, Kirsten D ^a,b,h   Demichelis, Francesca ^a,b   Sboner, Andrea ^c   Hirsch, Michelle S ^a,b   Dal Cin, Paola ^a,b   Struckmann, Kirsten ^d   Storz, Martina ^d   Scherrer, Simone ^d   Schmid, Daniel M ^d   Strebel, Räto T ^d   Probst Hensch, Nicole M ^d   Gerstein, Mark ^c,e   Moch, Holger ^d   Rubin, Mark A ^a,b,f,g,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Yale University   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h Universitatsklinik fur Dermatologie   (Austria)

ⁱ NONE   (United States)

Author keywords

Clear cell renal cell cancer; Cytogenetics; Cytokeratin; Gene expression profiling; Prognosis

Indexed keywords

CYTOKERATIN; CYTOKERATIN 19; CYTOKERATIN 7; MATRIX METALLOPROTEINASE 14; UVOMORULIN;

ARTICLE; CANCER GRADING; CHROMOSOME 3; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CLEAR CELL CARCINOMA; CYTOGENETICS; FOLLOW UP; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATASES; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 3; CYTOGENETIC ANALYSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; KERATIN-7; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 14; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 46049109740     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23565     Document Type: Article

References (43)

1. Eble JN, Sauter G, Epstein JI, Sesterhann IAE. World Health Organization classification of tumours. Pathology and genetics of tumours of the male urinary system and male genital organs. Lyon: IARC Press, vol. 1, 2004.
2. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-3.
3. Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K. Classification of renal cell carcinoma: workgroup no. I. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987-9.
4. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-24.
5. Moch H, Presti JC, Jr, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, Waldman FM. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996;56:27-30.
6. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease. Am J Clin Pathol 1999;111:539-43.
7. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604-14.
8. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res 1993;62:89-124.
9. Steiner G, Sidransky D. Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites. Am J Pathol 1996;149:1791-5.
10. van den Berg E, Dijkhuizen T, Oosterhuis JW, Geurts van Kessel A, de Jong B, Storkel S. Cytogenetic classification of renal cell cancer. Cancer Genet Cytogenet 1997;95:103-7.
11. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001;159:179-92.
12. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, et al. Renal carcinomas with the t(6;11 )(p21;q12): clinicopathologic features and demonstration of the specific α-TFEB gene fusion by immunohistochemistry. RT-PCR, and DNA PCR. Am J Surg Pathol 2005;29:230-40.
13. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, Eble JN, Struckmann K, Schraml P, Moch H. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004;28:1117-32.
14. Langner C, Wegscheider BJ, Ratschek M, Schips L, Zigeuner R. Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: a systematic analysis of 233 tumors. Virchows Arch 2004;444:127-34.
15. Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P, Young A, de Peralta-Venturina M, Amin MB. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am. J Surg. Pathol. 2005;29:747-54.
16. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
17. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol 1990;111:567-80.
18. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-39.
19. Hughson M, Johnson L, Silva F, Kovacs G. Nonpapillary and papillary renal cell carcinoma: a cytogenetic and phenotypic study. Mod Pathol 1993;6:449-56.
20. Cao Y, Karsten U, Zerban H, Bannasch P. Expression of MUC1. Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions. Virchows Arch 2000;436:119-26.
21. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
22. Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener PA, Moch H, Rubin MA. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 2007;38:1454-62.
23. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004;64:3814-22.
24. Sewalt RG, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, Satijn DP, Hendrix T, van Driel R, Otte AP. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 1998;18:3586-95.
25. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64:6854-7.
26. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999;154:981-6.
27. Guo P, Imanishi Y, Cackowski FC, Jarzynka MJ, Tao HQ, Nishikawa R, Hirose T, Hu B, Cheng SY. Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 2005;166:877-90.
28. Norris AM, Woodruff RD, D'Agostino RB, Jr., Clodfelter JE, Scarpinato KD. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate 2007;67:214-25.
29. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996;2:1879-85.
30. Buhler H, Schaller G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 2005;3:365-71.
31. Pankov R, Simcha I, Zoller M, Oshima RG, Ben-Ze'ev A. Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSp73 adenocarcinoma. Cell Sci 1997;110 (Part 8):965-74.
32. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast. Cancer. Res Treat 1994;31:325-35.
33. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992;150:534-44.
34. Moch H, Schraml P, Bubendorf L, Richter J, Gasser TC, Mihatsch MJ, Sauter G. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization. Cancer Res 1998;58:2304-9.
35. Yoshida M, Ohyashiki K, Ochi H, Gibas Z, Pontes J, Prout G, Huben R, Sandberg A. Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res 1986;46:2139-47.
36. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987;327:721-7.
37. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte Rl, Altman RB, Brown PO, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9.
38. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
39. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
40. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8.
41. Nagase H, Woessner JF,Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
42. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
43. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.